Drug intelligence / Profile preview

remestemcel-L-rknd

Development stage: Approved
Lead developer: Mesoblast
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

Remestemcel-L-rknd is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. It contains mesenchymal stromal cells isolated from the bone marrow of unrelated and human leukocyte antigen (HLA)-unmatched healthy adult donors. These cells have the ability to differentiate into different tissue types. The therapy is administered intravenously and is primarily indicated for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. It is the first FDA-approved MSC therapy in the United States, receiving approval in December 2024.

Brand names: RyoncilProchymalNestaCellTEMCELL HS Inj.
Other names: remestemcel-Ladult human mesenchymal stem cellsallogeneic human mesenchymal stem cellhMSC

Beyond the preview

Go deeper on remestemcel-L-rknd.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on remestemcel-L-rknd.

Explore the full profile